| Total Capacity | 614 KLPost-expansion |
|---|---|
| Market Cap | ₹6,232.4 CrPharmaceuticals |
| Revenue TTM | ₹1,950.6 CrOperating Revenue |
| RSI | 75.2Overbought Zone |
Key highlights
- Installed reactor capacity for API and CDMO increased by 79 KL to reach a total of 614 KL
- Expansion project completed ahead of the previously indicated timeline
- Strengthens manufacturing readiness for ongoing scale-up of commercial CDMO supplies
- Net profit grew by 424.73% year-on-year in the latest quarter ending June 2026
- Strategy focuses on building a globally compliant and scalable manufacturing platform
Production Commenced — What It Means
Morepen Laboratories has finalized the first stage of its manufacturing capacity enhancement, bringing its total installed reactor capacity to 614 KL. This addition of 79 KL specifically targets the Active Pharmaceutical Ingredient (API) and Contract Development and Manufacturing Organization (CDMO) segments. The project was executed ahead of its projected timeline, showcasing operational efficiency at its manufacturing facilities.
This expansion is designed to facilitate the scale-up of commercial supplies for global partners while maintaining the momentum of the company’s existing generic API business, focusing on long-duration customer partnerships and sustained growth.
Strategic Path to This Milestone
- Transitioning from a generic-heavy portfolio toward specialized and scalable CDMO services
- Investing in globally compliant infrastructure to meet stringent regulatory standards in international markets
- Milestone achieved ahead of schedule as part of a multi-phase manufacturing strategy
- Enhancing manufacturing readiness to handle larger volumes for future customer programs
- Building a larger platform to support sustained growth across the API business vertical
Financial Context and Revenue Impact
The capacity ramp-up coincides with a period of significant financial growth for the company. In the quarter ending June 2026, Morepen reported a 424.73% year-on-year surge in net profit to ₹56.4 crore, driven by a 34.07% increase in quarterly revenue. The company maintains an operating profit margin of 14.48%.
With a trailing twelve-month (TTM) revenue of ₹1,950.58 crore, the additional reactor capacity is expected to further optimize asset utilization. The stock’s price-to-earnings growth (PEG) ratio of 0.86 stands well below the sector average of 2.82, reflecting its current growth trajectory relative to valuation.
Sector Tailwinds
The Indian pharmaceutical sector is witnessing a surge in CDMO demand as global innovators prioritize cost-efficiency and supply chain resilience. Morepen’s focus on API and CDMO aligns with the broader industry trend of vertical integration and increased domestic manufacturing capabilities. The sector has seen a revenue growth of 15.53% YoY, while Morepen’s 34.07% growth suggests it is capturing significant market share.
The move to expand reactor capacity positions the firm to capitalize on the increasing outsourcing of complex chemical synthesis by global biotech and pharmaceutical companies seeking diversified manufacturing bases.
| Share price | ₹113.74 |
|---|---|
| Market capitalisation | ₹6,232.43 Cr |
| Revenue (annual) | ₹1,805.69 Cr |
| Net profit (annual) | ₹94.88 Cr |
| Revenue (latest quarter) | ₹570.13 Cr+17.62% vs previous quarter |
| Net profit (latest quarter) | ₹56.40 Cr+258.21% vs previous quarter |
| P/E (TTM) | 44.35×Sector 48.23× |
| Promoter holding | 35.65%0.00% QoQ |
| FII holding | 1.46%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Morepen Laboratories Limited announcing the successful completion of the first phase of its manufacturing capacity expansion program. Market figures from a third-party data provider.
